Lateral Canthal Lines Clinical Trial
Official title:
A Phase II, Multi-Centre, Randomised, Double-blind, Dose-Ranging Study Comparing the Efficacy and Safety of a Single Treatment With 15, 30 or 45 Units (Per Eye) of Dysport to Placebo in the Symptomatic Treatment of Lateral Canthal Lines (Crow's Feet)
Despite the wealth of information in the literature regarding the cosmetic applications of botulinum type A toxin (BoNT-A), and the widespread use of the BoNT-A for cosmetic applications, the number of randomised, controlled clinical trials is small. Much of the published information is based on open-label studies or anecdotal data. Of the robust trial data that is available, the vast majority relates to the treatment of glabellar lines, and there is little data available regarding the use of BoNT-A in lateral canthal lines. This study aims to determine the optimum dose for the use of BoNT-A in this area.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02248844 -
Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea
|
||
| Completed |
NCT02195687 -
BOTOX® in the Treatment of Crow's Feet Lines in China
|
Phase 3 | |
| Completed |
NCT01951742 -
Dose Finding Study In Subjects With Crow's Feet
|
Phase 2 | |
| Completed |
NCT03721016 -
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
|
Phase 3 | |
| Completed |
NCT03326856 -
ET-01 in Subjects With Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT04157686 -
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
|
Phase 3 | |
| Completed |
NCT03839693 -
ET-01 in Subjects With Lateral Canthal Lines, LCL-208
|
Phase 2 | |
| Completed |
NCT03923634 -
Princess® RICH for the Correction of Fine Lines
|
N/A | |
| Completed |
NCT03732833 -
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
|
Phase 3 | |
| Completed |
NCT00888914 -
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT04143854 -
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT01358695 -
Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet
|
Phase 2 | |
| Completed |
NCT01124565 -
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
|
Phase 2 | |
| Completed |
NCT01809964 -
Clinical Trial to Evaluate ANT-1401 in Crow's Feet
|
Phase 2 | |
| Completed |
NCT03911102 -
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT00968825 -
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT04225260 -
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
|
Phase 3 | |
| Completed |
NCT01064518 -
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
|
Phase 2 | |
| Completed |
NCT00884234 -
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT04249687 -
Treatment of Moderate to Severe Lateral Canthal Lines
|
Phase 3 |